BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-696@pharmaconomics
DTSTAMP:20260707T033823Z
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20260102
SUMMARY:URGN Approval — ZUSDURI
DESCRIPTION:A final FDA approval decision on ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is expected Jan 1\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/ex_956006.htm\n\nTrack it: https://pharmaconomics.com/e/696
URL:https://pharmaconomics.com/e/696
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:URGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR